Bagsværd, Denmark, 20 November 2023 – On 6 November 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Rules”). This programme is part of the overall share repurchase programme of up to DKK 30 billion to be executed during a 12-month period beginning 1 February 2023.
Under the programme initiated 6 November 2023, Novo Nordisk will repurchase B shares for an amount up to DKK 4.1 billion in the period from 7 November 2023 to 29 January 2024.
Since the announcement of the programme, the following transactions have been made:
Number of B shares (of DKK 0.10)Average purchase priceTransaction value, DKKAccumulated, last announcement440,000 310,784,17513 November 2023110,000708.4177,924,78714 November 2023113,000692.5978,263,12615 November 2023113,000676.2576,416,16116 November 2023110,000678.9174,679,69417 November 2023110,000694.3276,374,652Accumulated under the programme996,000 694,442,596
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
Transactions related to Novo Nordisk’s incentive programmes have resulted in a net transfer from Novo Nordisk of 134,052 B shares in the period from 7 November 2023 to 16 November 2023. The shares in these transactions were not part of the Safe Harbour repurchase programme.
With the transactions stated above, Novo Nordisk owns a total of 49,000,054 B shares of DKK 0.10 as treasury shares, corresponding to 1.1% of the share capital. The total amount of A and B shares of DKK 0.10 in the company is 4,510,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 30 billion during a 12-month period beginning 1 February 2023. As of 17 November 2023, Novo Nordisk has since 1 February 2023 repurchased a total of 45,103,778 B shares of DKK 0.10
